SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter-2 (SGLT2) inhibition should be used as a foundational therapy for chronic kidney disease as SGLT2 inhibitors might substantially slow the progression of chronic kidney disease in people with type 2 diabetes (40, 41).